Gilead Sciences’ hepatitis drug patent faces legal challenge
International group representing doctors and patient have launched a fresh challenge to the patent on Gilead Sciences’ hepatitis C drug Sofosbuvir at the European patent office in order to increase access to treatment. Sofosbuvir is sold by the US drugmaker as Sovaldi and is included in other hepatitis C medicine such as Harvoni and [...]
